Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Revitol Cellulite Cream

Celera Presents Data Replicating Its Immunodiagnostic Assay To Detect Lung Cancer From Blood Serum
Celera Corporation (NASDAQ:CRA) announced yesterday the presentation of data replicating its novel mass spectrometry-based approach to identify and validate circulating protein biomarkers that detect non-small cell lung cancer (NSCLC) in an independent cohort of individuals with lung cancer. This study was performed in collaboration with scientists at NYU Langone Medical Center, NY. A key outcome of the study was the validation of a 9 biomarker immunoassay on a cohort of samples that is enriched for stage I disease, important for screening of early stage disease. The assay detected lung cancer with 92% sensitivity at 93% specificity. The panel also accurately distinguished malignant cases from benign lung disease. The data is being presented at the 13th World Conference on Lung Cancer as part of the International Association for the Study of Lung Cancer (IASLC) in San Francisco, CA. Don't forget to buy zoloft online no prescription.

Promising New Drug Combination For Patients With Sleeping Sickness
Human African trypanosomiasis (HAT) or sleeping sickness affects tens of thousands of people every year in sub-Saharan Africa. It is a fatal disease with few treatment options. According to an article in this week"s issue of The Lancet, Nifurtimox in combination with eflornithine is safe, effective, and more affordable than current treatments for sleeping sickness. This new drug combination should be implemented as a matter of priority by control programmes across sub-Saharan Africa.

generic viagra online


News of the day
Are Blood Transfusions Bad For Your Health?
The August issue of the journal Anesthesiology, contains a study on potential long-term adverse effects resulting from blood transfusion and reveals that moderate amounts of transfused blood in patients in patients undergoing cardiac surgery did not lead to long-term health problems or increased death rates for the majority of recipients.
Endocrinology

HHS Purchases Additional H1N1 Vaccine Ingredients

HHS Secretary Kathleen Sebelius announced today that the department will commit $884 million to purchase additional supplies of two key ingredients for potential H1N1 vaccine to further prepare the nation for a potential resurgence of the 2009 H1N1 virus. "We recognize that preparedness is shared responsibility between federal, tribal, state, local governments, private organizations and individuals. We are doing our part to be as prepared as possible for the impact that this infectious disease could have on our country," Secretary Sebelius said. "Vaccines may serve an important role in that preparedness. The action we are taking today will provide flexibility in a future immunization program, if a program is recommended." The funds will be used to place additional orders for bulk H1N1 antigen and adjuvant on existing contracts with Sanofi Pasteur, MedImmune, GlaxoSmithKline and Novartis. The vaccine ingredients will become a part of the pandemic stockpile, for use if a vaccination campaign is necessary. Antigen is the active ingredient in a vaccine that causes the human body"s immune system to develop antibodies that help fight an invading virus. Depending on the results of clinical studies, adjuvant could be added to a vaccine to boost the immune system"s response and potentially reduce the amount of antigen necessary for the body to recognize and fight a virus. In May, Secretary Sebelius directed approximately $1 billion to be used for the development of a vaccine and for clinical studies to determine dose level and assess the safety and effectiveness of potential vaccines. The Biomedical Advanced Research and Development Authority (BARDA) in the HHS Office of the Assistant Secretary for Preparedness and Response established the existing contracts with these companies in 2004 as part of the National Strategy for Pandemic Influenza. More information about today"s contract action is available here. For the latest on the 2009 Influenza A H1N1 virus, see http://www.flu.gov. To learn more about the National Strategy for Pandemic Influenza visit http://www.flu.gov/plan/federal/pandemic-influenza.pdf. More about BARDA is available at http://www.hhs.gov/aspr/barda/index.html. HHS


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009